NeuroOne® to Host Investor Call About Recent Disclosures Tomorrow March 29th at 10:00 am ET
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on March 29, 2022, at 10:00 am ET, to discuss recent disclosures related to its 510(k) clearance request for the Evo® sEEG Electrode.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on March 29, 2022, at 10:00 am ET, to discuss recent disclosures related to its 510(k) clearance request for the Evo® sEEG Electrode. This device is already cleared for temporary use of less than 24 hours and seeks approval for less than 30 days. Investors and interested parties can join via the provided dial-in numbers or access the live webcast. The call aims to clarify the recent 8-K filing and answer participant questions.
Details
News Market Reaction – NMTC
The recorded move for NMTC in the trading session of this news was -0.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., March 28, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will host a conference call to discuss recent disclosures tomorrow, March 29, 2022, at 10:00 am Eastern Time. The purpose of the call is to provide clarification and answer questions regarding disclosure included in the Company's recent Current Report on Form 8-K filed on Friday, March 25, 2022 about its 510(k) clearance request to the FDA for its Evo® sEEG Electrode for less than 30-day use. The device has already been 510(k) cleared for temporary (less than 24 hours) use.
10:00 am ET, Tuesday, March 29, 2022
Participant Dial-In:
877-407-8293 / +1 201-689-8349
Live and archived webcast:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=TiuTgwf3
Telephone Replay
877-660-6853 / 201-612-7415
End Date: 2022-04-11
Access ID: 13728487
On the call, management will answer questions submitted in advance. To submit a question, please email questions@n1mtc.com.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-host-investor-call-about-recent-disclosures-tomorrow-march-29th-at-1000-am-et-301512224.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.